CVRx Launches BENEFIT‑HF Trial to Expand Barostim’s Heart‑Failure Reach
CVRx launches BENEFIT‑HF trial to test Barostim’s effectiveness in a wider heart‑failure population, aiming for broader reimbursement and market growth.
2 minutes to read
CVRx Inc